Novel adenosine analogues and their use as pharmaceutical agents
CA 2490253 A1 · Owner: Aventis Pharma Deutschland Gmbh · Inventors: Mueller, Guenter; Bigot, Antony; Jaehne, Gerhard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compounds according to the general formula (I), wherein R1, A, B, Q, T, W and X have the meanings given in the description. These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 26, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 26, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 26, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.